Johnson & Johnson kept just a sliver of third-quarter sales as profit while revenue rose

Johnson & Johnson, the US healthcare group, reported revenue of USD 25.4bn for the third quarter of 2026 (USD), up 5.9% from USD 24.0bn a year earlier. Profit moved the other way. Net profit fell to USD 210m from USD 5.2bn, and the net margin narrowed by 20.6 pp to 0.8% from 21.5%. The group kept only 0.8% of sales as profit, against 21.5% in the same quarter of 2025. Cash ended the quarter at USD 16.9bn, down from USD 18.2bn.

A drop this size, while sales grow, usually points below the revenue line: a large one-off charge, a settlement, a write-down or a tax item can erase a quarter of profit without touching sales. Revenue alone does not explain it. The balance sheet looks calm. Equity rose to USD 81.5bn, and the equity ratio, the share of assets funded by owners, held at 41.3%. I would watch whether the margin returns to its earlier level in the next quarterly report.